Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Spigel

Showing results (1-10 of 220) with videos related to

Pageof 22
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 20, 2012
PARP inhibitors in lung cancerDavid R Spigel
Biotechnology Healthcare|April 6, 2012
The value of observational cohort studies for cancer drugsDavid R Spigel
Lancet (London, England)|August 23, 2003
HER2 and surgery: more questions to answerDavid R Spigel
Current Treatment Options in Oncology|November 10, 2012
Treatment update in small-cell lung cancer: from limited to extensive diseaseDavid R Spigel
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
Evolving role of irinotecan in small-cell lung cancerDavid R Spigel, F Anthony Greco
Cancer Medicine|August 28, 2015
Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistanceRobert M Jotte, David R Spigel
Seminars in Surgical Oncology|September 26, 2003
Chemotherapy in metastatic and locally advanced non-small cell lung cancerDavid R Spigel, F Anthony Greco
Current Treatment Options in Oncology|June 12, 2002
HER2 overexpressing metastatic breast cancerDavid R Spigel, Harold J Burstein
Clinical Breast Cancer|January 13, 2004
Trastuzumab regimens for HER2-overexpressing metastatic breast cancerDavid R Spigel, Harold J Burstein
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 3, 2013
Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approachesDavid R Spigel, Mark A Socinski
Pageof 22

Showing results (1-10 of 220) with videos related to

Sort By:
Pageof 22
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 20, 2012
PARP inhibitors in lung cancerDavid R Spigel
Biotechnology Healthcare|April 6, 2012
The value of observational cohort studies for cancer drugsDavid R Spigel
Lancet (London, England)|August 23, 2003
HER2 and surgery: more questions to answerDavid R Spigel
Current Treatment Options in Oncology|November 10, 2012
Treatment update in small-cell lung cancer: from limited to extensive diseaseDavid R Spigel
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
Evolving role of irinotecan in small-cell lung cancerDavid R Spigel, F Anthony Greco
Cancer Medicine|August 28, 2015
Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistanceRobert M Jotte, David R Spigel
Seminars in Surgical Oncology|September 26, 2003
Chemotherapy in metastatic and locally advanced non-small cell lung cancerDavid R Spigel, F Anthony Greco
Current Treatment Options in Oncology|June 12, 2002
HER2 overexpressing metastatic breast cancerDavid R Spigel, Harold J Burstein
Clinical Breast Cancer|January 13, 2004
Trastuzumab regimens for HER2-overexpressing metastatic breast cancerDavid R Spigel, Harold J Burstein
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 3, 2013
Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approachesDavid R Spigel, Mark A Socinski
Pageof 22